RT Journal Article
SR Electronic
T1 Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.12.20230763
DO 10.1101/2020.11.12.20230763
A1 Adrian M Shields
A1 Sian E Faustini
A1 Marisol Perez-Toledo
A1 Sian Jossi
A1 Joel D Allen
A1 Saly Al-Taei
A1 Claire Backhouse
A1 Lynsey Dunbar
A1 Daniel Ebanks
A1 Beena Emmanuel
A1 Aduragbemi A Faniyi
A1 Mark I. Garvey
A1 Annabel Grinbergs
A1 Golaleh McGinnell
A1 Joanne O’Neill
A1 Yasunori Watanabe
A1 Max Crispin
A1 David. C Wraith
A1 Adam F Cunningham
A1 Mark T Drayson
A1 Alex G Richter
YR 2020
UL http://medrxiv.org/content/early/2020/11/16/2020.11.12.20230763.abstract
AB Objective To determine clinical and ethnodemographic correlates of serological responses against the SARS-CoV-2 spike glycoprotein following mild-to-moderate COVID-19.Design A retrospective cohort study of healthcare workers who had self-isolated due to COVID-19.Setting University Hospitals Birmingham NHS Foundation Trust, UK (UHBFT).Participants 956 health care workers were recruited by open invitation via UHBFT trust email and social media.Intervention Participants volunteered a venous blood sample that was tested for the presence of anti-SARS-CoV-2 spike glycoprotein antibodies. Results were interpreted in the context of the symptoms of their original illness and ethnodemographic variables.Results Using an assay that simultaneously measures the combined IgG, IgA and IgM response against the spike glycoprotein (IgGAM), the overall seroprevalence within this cohort was 46.2% (n=442/956). The seroprevalence of immunoglobulin isotypes was 36.3%, 18.7% and 8.1% for IgG, IgA and IgM respectively. IgGAM identified serological responses in 40.6% (n=52/128) of symptomatic individuals who reported a negative SARS-CoV-2 PCR test. Increasing age, non-white ethnicity and obesity were independently associated with greater IgG antibody response against the spike glycoprotein. Self-reported fever and fatigue were associated with greater IgG and IgA responses against the spike glycoprotein. The combination of fever and/or cough and/or anosmia had a positive predictive value of 92.3% for seropositivity.Conclusions and relevance Assays employing combined antibody detection demonstrate enhanced seroepidemiological sensitivity and can detect prior viral exposure even when PCR swabs have been negative. We demonstrate an association between known ethnodemographic risk factors associated with mortality from COVID-19 and the magnitude of serological responses in mild-to-moderate disease. The combination of cough, and/or fever and/or anosmia identifies the majority of individuals who should self-isolate for COVID-19.Competing Interest StatementMTD reports personal fees from Abingdon Health, outside the submitted work. All other authors declare no competing interests.Funding StatementThis paper presents independent research supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (Grant Reference Number BRC-1215-20009). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The authors are grateful for funding from the Global Challenges Research Fund and The Institute for Global Innovation (IGI) of the University of Birmingham, and the UK Medical Research Council (Grant Reference Number MC PC 17183)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the London - Camden & Kings Cross Research Ethics Committee reference 20/HRA/1817. All participants provided written, informed consent prior to enrolment in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymised dataset will be made available on reasonable request. Proposals should be directed to the corresponding author.